<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31897">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057718</url>
  </required_header>
  <id_info>
    <org_study_id>LUM001-501</org_study_id>
    <secondary_id>2013-003833-14</secondary_id>
    <nct_id>NCT02057718</nct_id>
  </id_info>
  <brief_title>Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis</brief_title>
  <acronym>INDIGO</acronym>
  <official_title>Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumena Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Childhood Liver Disease Research and Education Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lumena Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study in children with Progressive Familial Intrahepatic Cholestasis
      (PFIC) designed to evaluate the safety and efficacy of LUM001.  Efficacy will be assessed by
      evaluating the effect of LUM001 on the biochemical markers and pruritus associated with
      PFIC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in fasting serum bile acids from baseline to Week 13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in liver enzymes and pruritus from baseline to Week 13</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 48</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis (PFIC)</condition>
  <arm_group>
    <arm_group_label>LUM001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUM001 administered orally once each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUM001</intervention_name>
    <arm_group_label>LUM001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Progressive Familial Intrahepatic Cholestasis

          2. Ability to understand and willingness to sign informed consent/assent prior to
             initiation

        Exclusion Criteria:

          1. Surgical disruption of the enterohepatic circulation

          2. Liver transplant

          3. History or presence of other concomitant liver disease

          4. Females who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Dorenbaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lumena Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Barbat, BSN, RN</last_name>
    <phone>858-461-0694</phone>
    <email>info@lumenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palaniswamy Karthikeyan</last_name>
      <email>pkarthikeyan@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Harpreet Grewal</last_name>
      <email>harpreet.grewal@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Richard J Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.lumenapharma.com</url>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
